Lynch & Associates IN increased its stake in Colgate-Palmolive Company (NYSE:CL) by 6.9% during the second quarter, Holdings Channel reports. The institutional investor owned 31,592 shares of the company’s stock after buying an additional 2,050 shares during the period. Lynch & Associates IN’s holdings in Colgate-Palmolive were worth $2,342,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. American Beacon Advisors Inc. bought a new stake in Colgate-Palmolive during the first quarter valued at $102,000. Proficio Capital Partners LLC increased its stake in Colgate-Palmolive by 16.9% in the first quarter. Proficio Capital Partners LLC now owns 1,432 shares of the company’s stock valued at $107,000 after buying an additional 207 shares in the last quarter. Harbour Capital Advisors LLC bought a new stake in Colgate-Palmolive during the first quarter valued at $121,000. AlphaMark Advisors LLC increased its stake in Colgate-Palmolive by 452.1% in the first quarter. AlphaMark Advisors LLC now owns 1,673 shares of the company’s stock valued at $122,000 after buying an additional 1,370 shares in the last quarter. Finally, Mascoma Wealth Management LLC bought a new stake in Colgate-Palmolive during the second quarter valued at $131,000. 73.85% of the stock is currently owned by institutional investors.

Colgate-Palmolive Company (NYSE:CL) traded down 0.41% during trading on Friday, hitting $71.26. 2,023,502 shares of the company traded hands. Colgate-Palmolive Company has a 52-week low of $63.43 and a 52-week high of $77.27. The firm has a market cap of $62.77 billion, a price-to-earnings ratio of 26.48 and a beta of 0.80. The company’s 50-day moving average is $72.84 and its 200 day moving average is $72.74.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, July 21st. The company reported $0.72 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.72. Colgate-Palmolive had a net margin of 15.83% and a return on equity of 3,121.95%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same period last year, the firm posted $0.70 EPS. Colgate-Palmolive’s quarterly revenue was down .5% on a year-over-year basis. On average, equities analysts anticipate that Colgate-Palmolive Company will post $2.89 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Tuesday, July 18th will be given a $0.40 dividend. The ex-dividend date is Friday, July 14th. This represents a $1.60 dividend on an annualized basis and a yield of 2.25%. Colgate-Palmolive’s dividend payout ratio (DPR) is 59.48%.

TRADEMARK VIOLATION NOTICE: “Colgate-Palmolive Company (CL) Shares Bought by Lynch & Associates IN” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/colgate-palmolive-company-cl-shares-bought-by-lynch-associates-in/1479685.html.

Several research firms have recently commented on CL. Zacks Investment Research downgraded shares of Colgate-Palmolive from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $74.00 price objective on shares of Colgate-Palmolive in a report on Thursday, May 25th. UBS AG reaffirmed a “neutral” rating and issued a $78.00 price objective (down from $79.00) on shares of Colgate-Palmolive in a report on Tuesday, May 2nd. BidaskClub downgraded shares of Colgate-Palmolive from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 12th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $79.00 price objective (up from $77.00) on shares of Colgate-Palmolive in a report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $75.82.

In related news, Vice Chairman Franck J. Moison sold 35,000 shares of Colgate-Palmolive stock in a transaction on Monday, August 7th. The shares were sold at an average price of $71.52, for a total value of $2,503,200.00. Following the transaction, the insider now directly owns 201,411 shares in the company, valued at approximately $14,404,914.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patricia Verduin sold 3,833 shares of Colgate-Palmolive stock in a transaction on Monday, July 17th. The shares were sold at an average price of $72.41, for a total transaction of $277,547.53. Following the completion of the transaction, the insider now owns 53,022 shares in the company, valued at $3,839,323.02. The disclosure for this sale can be found here. Over the last quarter, insiders sold 203,969 shares of company stock worth $14,711,068. 1.02% of the stock is currently owned by insiders.

About Colgate-Palmolive

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive Company and related companies with Analyst Ratings Network's FREE daily email newsletter.